Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haluska

Showing results (301-310 of 366) with videos related to

Pageof 37
Sort By:
Molecular Cancer Therapeutics|January 12, 2011
Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924Xiaonan Hou, Fei Huang, Joan M Carboni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancerDaniel D Karp, Luis G Paz-Ares, Silvia Novello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptorJohann S de Bono, Gerhardt Attard, Alex Adjei, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 21, 2005
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901John D Roberts, Donna Niedzwiecki, William E Carson, et al.
Cancer Chemotherapy and Pharmacology|April 24, 2013
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignanciesDaryl Sonnichsen, David J Dorer, Jorge Cortes, et al.
BMC Nephrology|July 19, 2015
Left ventricular global longitudinal strain is associated with cardiovascular risk factors and arterial stiffness in chronic kidney diseaseRathika Krishnasamy, Carmel M Hawley, Tony Stanton, et al.
Investigational New Drugs|September 13, 2021
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignanciesJoleen M Hubbard, Jun Yin, Erin L Schenk, et al.
Cancer Research|January 7, 2006
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417Paul Haluska, Joan M Carboni, David A Loegering, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabineAntonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
Cancer Research|March 12, 2009
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cellsMarta Santisteban, Jennifer M Reiman, Michael K Asiedu, et al.
Pageof 37

Showing results (301-310 of 366) with videos related to

Sort By:
Pageof 37
Molecular Cancer Therapeutics|January 12, 2011
Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924Xiaonan Hou, Fei Huang, Joan M Carboni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancerDaniel D Karp, Luis G Paz-Ares, Silvia Novello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptorJohann S de Bono, Gerhardt Attard, Alex Adjei, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 21, 2005
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901John D Roberts, Donna Niedzwiecki, William E Carson, et al.
Cancer Chemotherapy and Pharmacology|April 24, 2013
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignanciesDaryl Sonnichsen, David J Dorer, Jorge Cortes, et al.
BMC Nephrology|July 19, 2015
Left ventricular global longitudinal strain is associated with cardiovascular risk factors and arterial stiffness in chronic kidney diseaseRathika Krishnasamy, Carmel M Hawley, Tony Stanton, et al.
Investigational New Drugs|September 13, 2021
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignanciesJoleen M Hubbard, Jun Yin, Erin L Schenk, et al.
Cancer Research|January 7, 2006
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417Paul Haluska, Joan M Carboni, David A Loegering, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabineAntonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
Cancer Research|March 12, 2009
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cellsMarta Santisteban, Jennifer M Reiman, Michael K Asiedu, et al.
Pageof 37